10-Q · May 11, 2026
Liquidia Corporation reported exceptionally strong Q1 2026 results, with total revenues hitting $132.9 million, representing a significant increase compared to prior periods. The financial highlights include net income…
Earnings analysis · 10-Q
LQDA earnings analysis
Filed August 12, 2026 · Our reading of the company's report
The latest report
The filing indicates that Liquidia maintained profitability and positive operating cash flow through the first two quarters of 2026, although the provided excerpt does not contain the current quarter’s revenue, EPS,…
Read full summary
The filing indicates that Liquidia maintained profitability and positive operating cash flow through the first two quarters of 2026, although the provided excerpt does not contain the current quarter’s revenue, EPS, margins, segment results, balance-sheet balances or cash-flow amounts. The investment case remains concentrated in YUTREPIA, with an accumulated deficit of $498.7 million and a $15.0 million minimum cash covenant under the HCR facility. Ongoing United Therapeutics litigation, the CADD-MS-3 pump replacement issue, and newly emphasized tariff and geopolitical risks offset the improving operating trajectory.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Profitability Continued Through Q2
Management states that the company achieved profitability and positive cash flows in both the first and second quarters of 2026, extending the improvement reflected in the supplied history from a $0.52 diluted EPS profit and $50 million of FCF in Q1 2026.
-
Losses Narrowed Historically
The company had an accumulated deficit of $498.7 million as of June 30, 2026, but reported historical annual net losses of $68.9 million in 2025 versus $128.3 million in 2024.
-
Controls Remained Effective
Disclosure controls and procedures were concluded effective at the reasonable assurance level as of June 30, 2026, and management reported no changes in internal control that materially affected, or were reasonably likely to materially affect, financial reporting.
-
Broad Public Share Availability
As of July 29, 2026, 83,139,121 shares, or 92.9% of outstanding shares, were freely tradable without restriction or further registration under the Securities Act.
What to watch
-
YUTREPIA Litigation Remains Critical
United Therapeutics has multiple pending patent and trade-secret proceedings, including the ‘327 Patent Litigation and the ‘782 Patent Litigation. The company states that an adverse outcome could require YUTREPIA to be withdrawn or could stop commercialization for one or both indications; the ‘327 trial was held in June 2025 and the ‘782 complaint was filed in May 2025.
-
Treprostinil Pump Constraint
The company states that ICU Medical no longer manufactures or supports the CADD-MS-3 infusion pump used for subcutaneous Treprostinil Injection. Available pumps are expected to be sufficient only through at least the end of 2026, and neither Liquidia nor Sandoz had submitted a 510(k) application for a replacement pump as of the filing.
-
Tariff and Supply-Chain Exposure
The filing newly emphasizes tariff and geopolitical exposure across the supply chain: APIs, devices and raw materials are sourced from South Korea, Taiwan, China, Italy and elsewhere, while Sandoz sources treprostinil from Canada. It also cites an April 2026 executive order seeking a 100% tariff on certain imported branded or patented pharmaceuticals.
-
HCR Covenant and Liquidity Risk
The company must maintain a minimum cash balance of $15.0 million under its HCR financing agreement. A covenant breach or material adverse event could permit acceleration and foreclosure on collateral, including intellectual property.
-
Concentration in YUTREPIA
The company remains primarily dependent on YUTREPIA and L606 while having only one approved product; YUTREPIA received FDA approval in May 2025 and began commercialization in June 2025. The filing states that sustained revenue, profitability and positive cash flow from YUTREPIA remain uncertain.
Management's outlook
The provided 10-Q excerpt does not include quantitative Q2 2026 revenue, EPS, margin, segment, or cash-flow guidance. Management states that profitability and positive cash flow were achieved in the first two quarters of 2026, but no forward numerical outlook is provided.
Earlier filings 4
10-K · March 5, 2026
Liquidia’s 10-K documents a clear commercial inflection following FDA approval of YUTREPIA in May 2025 and launch in June 2025, with revenue ramping to $92,021,000 in Q4 2025 and margins and cash flow turning positive.…
10-Q · May 8, 2025
Liquidia reported Q1 revenue of $3,120,000 (up from $2,972,000 year-over-year) and a GAAP net loss per share of $(0.45) (vs. $(0.40) year‑ago). Gross margin held at ~51.4% while operating loss widened to $35,425,000,…
10-Q · August 7, 2024
Liquidia reported Q2 revenue of $3.659M (down $1.127M or -23.6% YoY from $4.786M; up $0.687M or +23.1% QoQ from $2.972M). Gross margin improved sequentially to 59.2% but collapsed YoY from ~86.0%; operating loss…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.